Want to see FDMT full AI Analyst Report?
FDMT Stock Chart & Stats
$10.07
$0.31(3.08%)
At close: 4:00 PM EDT
$10.07
$0.31(3.08%)
Day’s Range― - ―
52-Week Range$5.97 - $16.93
Previous Close$10.76
Volume531.42K
Average Volume (3M)968.42K
Market Cap
$889.43M
Enterprise Value$612.50
Total Cash (Recent Filing)$361.33M
Total Debt (Recent Filing)$39.22M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Nov 11, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.72
Shares Outstanding55,244,210
10 Day Avg. Volume698,244
30 Day Avg. Volume968,420
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.86
Price to Sales (P/S)5.10
P/FCF Ratio-3.98
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$32.80Price Target Upside225.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.11
Revenue Forecast (FY)$13.18M
Bulls Say, Bears Say
Bulls Say
Sharp Revenue GrowthThe substantial revenue step-up indicates stronger collaboration, licensing, or milestone activity. Although revenue may remain variable, a larger commercial and partnership base can improve funding capacity and support continued clinical development.
Conservatively Levered Balance SheetVery low existing leverage gives FDMT greater flexibility than a heavily indebted biotech while it funds clinical programs. The sizable equity base provides some capacity to absorb development volatility and pursue strategic financing.
Promising 4D-150 Clinical DataDurable efficacy, reduced treatment burden, and favorable safety support advancing 4D-150 into Phase 3. If replicated in larger trials, these attributes could strengthen differentiation, partnering potential, and eventual market adoption.
Bears Say
Large And Persistent Net LossesFDMT remains far from breakeven despite higher revenue, leaving its outlook dependent on successful clinical execution and future financing or partnership proceeds. Continued losses can erode shareholder capital and limit strategic flexibility.
Heavy Operating Cash BurnThe scale of cash consumption reflects the substantial cost of advancing clinical-stage gene therapies. If burn remains elevated, FDMT may require repeated capital raises or additional partnerships, creating dilution and execution risk.
Funding Facility Adds Secured ObligationsThe facility expands near-term funding capacity but introduces floating interest costs, collateral restrictions, and covenant risk. Milestone-dependent tranches may not be fully available when needed, limiting flexibility if development results disappoint.
4D Molecular Therapeutics News
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $5.97 and its highest was $16.93 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
4D Molecular Therapeutics’s market cap is $889.43M.
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 80 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on Aug 13, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$1.017 by -$0.023.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -1.05.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 55,244,210 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$1.04 in its last earnings report, missing expectations of -$1.017. Following the earnings report the stock price went up 4.635%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Currently, no hedge funds are holding shares in FDMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4D Molecular Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.80 (225.72% Upside)
$32.80 (225.72% Upside)
Blogger Sentiment
Bullish
FDMT Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 56.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $117.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.01%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
FDMT Stock 12 Month Forecast
Average Price Target
$32.80
▲(225.72% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Design Therapeutics
―
Immuneering
―
Aura Biosciences Inc
―
Ownership Overview
1.85% Insiders
12.47% Mutual Funds
48.37% Other Institutional Investors
19.56% Public Companies and
Individual Investors